Biogen wins approval of at-home version of Alzheimer's drug Leqembi

2 hours ago 1

The U.S. FDA has approved a subcutaneous injection version of Biogen (NASDAQ:BIIB) and Eisai's (OTCPK:ESALF) Alzheimer's therapy Leqembi (lecanemab).
A key advantage of the new version, Leqembi IQLIK, is that it can be taken at home. Currently, the treatment is given via an infusion